Introduction:

In a landmark ruling, the Delhi High Court delivered a significant judgment in favor of Johnson & Johnson, a globally renowned pharmaceutical company, against counterfeit medical products being illegally sold under its registered trademarks ‘Surgicel,’ ‘Ligaclip,’ and ‘Ethicon.’ The lawsuit was initiated after Johnson & Johnson discovered large-scale counterfeiting and unauthorized sale of surgical devices, which posed serious risks to public health. The plaintiff argued that the defendants, led by Pritamdas Arora, the proprietor of M/s Medserve based in New Delhi, were engaged in a deliberate scheme to sell fake surgical products under their trademarks, jeopardizing patient safety. The case gained momentum after a neurosurgeon at the University of Kentucky Medical Center identified irregularities in a ‘Surgicel’-branded device during brain surgery in 2019, prompting an internal investigation. This led to the discovery that the counterfeit product had originated from India and was being distributed internationally. The defendants were accused of not only infringing trademarks but also engaging in Hawala transactions to launder illicit proceeds from their fraudulent activities. Despite multiple court orders, they failed to make full and honest disclosures regarding their business dealings. The High Court, after reviewing the overwhelming evidence, held that the counterfeit products posed a grave threat to public health, as they lacked sterility and quality control necessary for surgical use. The court condemned the defendants’ willful misrepresentation, including falsification of expiry dates on medical devices and an intercepted conversation where they planned to resolve complaints about infected products through bribery rather than corrective measures. The court awarded Rs. 2.34 crore as compensatory damages and Rs. 1 crore as exemplary damages, emphasizing that counterfeiting medical devices is not just a trademark violation but a crime endangering lives. Justice Amit Bansal’s decision reinforced the importance of strict action against counterfeit medical goods to ensure public safety and uphold consumer trust in genuine medical products.

Arguments of Both Sides:

The plaintiff, Johnson & Johnson, contended that it had been using the trademarks ‘Surgicel,’ ‘Ligaclip,’ and ‘Ethicon’ in relation to surgical devices since the 1990s. It argued that the products manufactured under these trademarks adhered to stringent quality control measures, ensuring their reliability for medical professionals worldwide. Johnson & Johnson traced the counterfeit products to defendant no.1, Pritamdas Arora, through a series of intermediaries, including Pure Care Traders in the UAE and Lion Heart Surgical Supply in Florida. The company claimed that the defendants had been selling counterfeit surgical devices, misleading medical professionals, and endangering public health. Johnson & Johnson also highlighted that counterfeit products were being exported internationally, violating not only Indian trademark laws but also global medical safety standards. The company provided extensive evidence, including documents seized during court-ordered inspections, which showed large-scale manufacturing and distribution of fake products under its brand name. The plaintiff further revealed that the defendants were engaged in Hawala transactions, evading regulatory oversight while making illicit profits from counterfeit goods.

The defendants, on the other hand, chose to evade court proceedings after an initial injunction was issued against them in 2019. Before disappearing from legal scrutiny, they initially claimed that they were only redistributing surgical devices purchased from third parties and had no role in counterfeiting. However, the evidence against them painted a different picture. Documents seized during inspections included fake invoices, falsified expiry dates on medical devices, and guides found at the defendants’ premises on how to distinguish genuine products from counterfeits—strongly indicating their premeditated intent to deceive. A recorded conversation revealed that when faced with complaints about infected surgical products, defendant no.1 suggested bribing the complainant instead of addressing the issue, showcasing blatant disregard for public health. The defendants’ continued non-cooperation with the court further confirmed their deliberate attempt to conceal the fraudulent operations.

Court’s Judgment:

The Delhi High Court, after reviewing all the evidence, ruled in favor of Johnson & Johnson, stating that the defendants’ actions were not merely a case of trademark infringement but a grave offense endangering human lives. Justice Amit Bansal emphasized that counterfeiting medical devices is a severe crime, as such products lack necessary sterility and quality controls required for surgical use. The court took serious note of the defendants’ attempts to mislead consumers, falsify expiry dates, and engage in Hawala transactions to launder illicit proceeds. Additionally, the discovery of guides on differentiating genuine and counterfeit products suggested a deliberate scheme to deceive medical professionals. The High Court found that the defendants’ conduct was malicious, given their refusal to cooperate with court orders and failure to disclose financial details. The court observed that the defendants’ primary intent was to exploit consumer trust for financial gain while jeopardizing public safety. Recognizing the gravity of the offense, the court imposed a total penalty of Rs. 3.34 crore on the defendants—Rs. 2.34 crore as compensatory damages and Rs. 1 crore as exemplary damages—to serve as a deterrent against such fraudulent activities in the medical sector. The court reaffirmed that counterfeit medical devices pose an unacceptable risk to public health, and strict legal measures must be taken to prevent their proliferation. In issuing the permanent injunction, the court barred the defendants from engaging in any further sale, distribution, or marketing of counterfeit surgical devices under Johnson & Johnson’s registered trademarks. This ruling sends a strong message against counterfeiting in the medical industry and reinforces the need for regulatory vigilance to protect patient safety.